Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer
Metrics: PDF 469 views | HTML 811 views | ?
Alfiah Noor1, Ijeoma Adaku Umelo1, Peter Kronenberger1,2, Philippe Giron1, Elly De Vlieghere3, Olivier De Wever3, Erik Teugels1 and Jacques De Grève1
1Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Brussels, Belgium
2Laboratory of Biotechnology, Department of Healthcare, Erasmushogeschool Brussel, Brussels, Belgium
3Laboratory of Experimental Cancer Research, Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
Jacques De Grève, email: Jacques.Degreve@uzbrussel.be
Alfiah Noor, email: firstname.lastname@example.org
Keywords: NSCLC; TRAIL; PLK1; cell cycle; combination therapy
Received: January 18, 2017 Accepted: May 31, 2018 Published: June 19, 2018
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells without causing damage to normal cells. However, some tumors are resistant to TRAIL monotherapy and clinical studies assessing targeted agents towards the TRAIL receptor have failed to show robust therapeutic activity. Evidence has shown that standard anti-mitotic drugs can induce synergistic apoptosis upon combination with TRAIL via cell cycle arrest. Polo like kinase-1 (PLK1) plays a critical role in different stages of cell cycle progression and mitosis. A number of investigations have demonstrated that PLK1 inhibition causes cell cycle arrest and mitotic catastrophe in non-small cell lung cancer (NSCLC), and we thus postulated that PLK1 inhibition could enhance TRAIL-induced apoptosis. We demonstrate that the combination of a TRAIL receptor agonist and a PLK1 inhibitor synergistically reduces cell viability, and strongly increases apoptosis in NSCLC cellular models. Consistent with our in vitro observations, this drug combination also significantly reduces tumor growth in vivo. Our data additionally reveal that G2/M cell cycle arrest and downregulation of Mcl-1 and signal transducer and activator of transcription 3 (STAT3) activity following PLK1 inhibition may contribute to the sensitization of TRAIL-induced apoptosis in NSCLC. Together, these data support the further exploration of combined TRAIL and PLK1 inhibition in the treatment of NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.